Clinical trials: Allogeneic Hematopoietic Stem Cell Transplantation
Acute Myeloid Leukemia
A Trial of the FMS-like Tyrosine Kinase 3 (FLT3) Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients With FLT3/Internal Tandem Duplication (ITD) Acute Myeloid Leukemia (AML)
The purpose of this study was to compare relapse-free survival between participants with FLT3/ITD AML in first morphologic complete remission (CR1) who underwent hematopoietic stem cell transplant (HCT) and were randomized to…
- Trial name
- NCT02997202
- Testing
- gilteritinib
- Where
- 118 sites in United States, Australia and 14 more
- Volunteers
- 356 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Graft Vs Host Disease
Alterations in Intestinal Microbiota, Metabolites, and Immune Cells in Allo-HSCT
This research project delves into the critical role of gut immunity in the occurrence and progression of acute graft-versus-host disease (aGVHD) post allogeneic hematopoietic stem cell transplantation (allo-HSCT).
- Trial name
- NCT06143501
- Testing
- Blood Sample, Stool Sample, Urine Sample
- Where
- China
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- The First Affiliated Hospital of Soochow University
Wounds
The Use of CureXcellTM in a Community Setting for the Treatment of Hard to Heal Wounds
The primary objective of the study is to define procedures for the use of CureXcellTM in the community through Clalit Health Services.
- Trial name
- NCT01113307
- Testing
- Activated allogeneic white blood cells
- Where
- 7 sites in Israel
- Volunteers
- 131 people
- Sponsor
- Macrocure Ltd.
Graft Vs Host Disease
Safety Study of Preimplantation Factor (PIF-1) to Treat Acute Steroid-Resistant Graft-Versus-Host Disease (GVHD)
The primary goal of this study is to determine the safety and tolerability of a novel peptide - preimplantation factor (PIF-1) - in patients who develop acute steroid-resistant graft-versus-host disease (GVHD) after matched bone…
- Trial name
- PIF1GVHD (NCT00517907)
- Testing
- Preimplantation factor (PIF-1)
- Where
- Israel
- Volunteers
- 6 people
- Sponsor
- Hadassah Medical Organization
Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)
Early Detection of Infectious and Noninfectious Lung Diseases Following Allogeneic Hematopoietic Stem Cell Transplantation
Background: Stem cell transplants (called hematopoietic stem cell transplantation, or HSCT) are used to treat various diseases. But when the cells for this procedure are donated by someone other than the person who receives the…
- Trial name
- NCT06093867
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Fanconi's Anemia, Myelodysplastic Syndromes
Study of Allogeneic Bone Marrow Transplantation Following Cyclophosphamide and Radiotherapy in Patients With Myelodysplastic Syndrome and Acute Leukemia Related to Fanconi's Anemia
OBJECTIVES: I. Determine the effectiveness of moderate dose cyclophosphamide and radiotherapy in terms of improving survival and reducing the morbidity following allogeneic bone marrow transplantation in patients with…
- Conditions
- Fanconi's Anemia, Myelodysplastic Syndromes, Leukemia, Nonlymphocytic, Acute, Leukemia, Lymphocytic, Acute
- Trial name
- NCT00005892
- Testing
- cyclophosphamide, Allogeneic Bone Marrow Transplantation
- Where
- United States
- Sponsor
- Fairview University Medical Center
Non-hodgkin Lymphoma,B Cell
Allogeneic TRAC Locus-inserted CD19-targeting STAR T Cell Therapy in r/r B-NHL
The team has developed the synthetic T cell receptor (TCR) and antigen receptor (STAR) T cells which were demonstrated safety in relapsed or refractory (r/r) B-cell non-Hodgkin' s lymphoma (B-NHL) (NCT05631912).
- Trial name
- NCT06321289
- Testing
- Allogeneic CD19-STAR T cell, Fludarabine, Cyclophosphamide
- Where
- 2 sites in China
- Volunteers
- 30 people
- Sponsor
- Chinese PLA General Hospital
Acute Myeloid Leukemia, Childhood
A Prospective Multicenter Clinical Trial of MRD-based Treatment Strategy in Children and Young Adults With AML
Minimal-residual disease (MRD) will be measured either by flow cytometry, or polymerase chain reaction (PCR) methods, in 3 check-points and it will be one of the decision-making control parameter for the optimal therapy tactics.
- Trial name
- NCT03846362
- Testing
- HSCT
- Where
- 2 sites in Russia
- Volunteers
- 500 people
- Sponsor
- Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Sickle Cell Disease, Thalassemia
Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation (HaploHCT) Following Reduced Intensity Conditioning (RIC) for Selected High Risk Non-Malignant Diseases
This is a Phase II study for the use of T-cell replete reduced intensity conditioning (RIC) haploidentical donor allogeneic hematopoietic cell transplantation (HaploHCT) for individuals with high-risk non-malignant diseases who…
- Conditions
- Sickle Cell Disease, Thalassemia, High Risk Hematologic Disorders, Cerebral Adrenoleukodystrophy
- Trial name
- NCT03367546
- Testing
- Blood and Marrow Transplant
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Acute Lymphoblastic Leukemia
Residual Disease Driven Strategy for CARCIK (CD19) in Adults/Pediatric BCP-ALL
This is a single arm, open-label, multi-center, phase II study to determine the activity and the safety of a therapeutic strategy that allows a second CARCIK-CD19 cells infusion, driven by the status of disease from one month…
- Trial name
- NCT05252403
- Testing
- PTG-CARCIK-CD19
- Where
- 2 sites in Italy
- Volunteers
- 35 people
- Sponsor
- Fondazione Matilde Tettamanti Menotti De Marchi Onlus
Epstein-Barr Virus+ Associated Post-transplant Lymphoproliferative Disease (EBV+ PTLD), Solid Organ Transplant Complications
A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy
The purpose of this study is to determine the clinical benefit and characterize the safety profile of tabelecleucel for the treatment of Epstein-Barr virus-associated post-transplant lymphoproliferative disease (EBV+ PTLD) in the…
- Conditions
- Epstein-Barr Virus+ Associated Post-transplant Lymphoproliferative Disease (EBV+ PTLD), Solid Organ Transplant Complications, Lymphoproliferative Disorders, Allogeneic Hematopoietic Cell Transplant
- Trial name
- ALLELE (NCT03394365)
- Testing
- tabelecleucel
- Where
- 71 sites in United States, Australia and 7 more
- Volunteers
- 115 people
- Sponsor
- Pierre Fabre Medicament
Idiopathic Pulmonary Fibrosis (IPF)
Allogeneic Human Cells (hMSC)in Patients With Idiopathic Pulmonary Fibrosis Via Intravenous Delivery (AETHER)
This is a phase I, randomized, blinded, placebo-controlled 9 subjects pilot safety run-in followed by an additional 16 randomized subjects for a total of 25 subjects.
- Trial name
- AETHER (NCT02013700)
- Testing
- Allogeneic Adult Human Mesenchymal Stem Cells (hMSCs)
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Joshua M Hare
Chronic Myeloproliferative Disorders, Leukemia
Busulfan, Fludarabine, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Stem Cell Transplant for Hematologic Cancer
RATIONALE: Giving low doses of chemotherapy, such as fludarabine and busulfan, before a donor peripheral blood stem cell transplant helps stop the growth of cancer cells.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- Bu Flu TBI (NCT00245037)
- Testing
- therapeutic allogeneic lymphocytes, busulfan, cyclosporine
- Where
- United States
- Volunteers
- 147 people
- Sponsor
- OHSU Knight Cancer Institute
High-Risk Acute Myeloid Leukemia
Clinical Study to Evaluate the Safety and Efficacy of γδ T Cells for the Prevention of Relapse After Allogeneic Transplantation in Patients With High-risk Acute Myeloid Leukemia
This is an investigator-initiated clinical trial evaluating the safety and efficacy of allogeneic γδ T cell infusion for relapse prevention in high-risk acute myeloid leukemia patients after transplantation.
- Trial name
- NCT07237230
- Testing
- allogeneic γδ T cell infusion
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Donghua Zhang
Refractory Multiple Myeloma, Stage I Multiple Myeloma
Vaccine Therapy in Treating Patients With Multiple Myeloma Who Have Undergone Stem Cell Transplantation
The purpose of this trial is to test the safety and immune response to four immunizations with this vaccine made from a protein produced by the patient's tumor.
- Conditions
- Refractory Multiple Myeloma, Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma
- Trial name
- NCT00002787
- Testing
- autologous immunoglobulin idiotype-KLH conjugate vaccine, sargramostim, aldesleukin
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma
Lenalidomide With or Without Rituximab in Treating Patients With Progressive or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Prolymphocytic Leukemia, or Non-Hodgkin Lymphoma Previously Treated With Donor Stem Cell Transplant
This phase II trial studies how well giving lenalidomide with or without rituximab works in treating patients with progressive or relapsed chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), prolymphocytic…
- Conditions
- Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Cutaneous B-cell Non-Hodgkin Lymphoma
- Trial name
- NCT01419795
- Testing
- lenalidomide, rituximab, pharmacological study
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Fred Hutchinson Cancer Center
Acute Myeloid Leukemia
Clofarabine and Low-Dose Total-Body Irradiation in Treating Patients With Acute Myeloid Leukemia Undergoing Donor Peripheral Blood Stem Cell Transplant
This phase II trial studies the side effects and how well clofarabine works when given together with low-dose total-body irradiation (TBI) in treating patients with acute myeloid leukemia (AML) undergoing donor peripheral blood…
- Trial name
- NCT01252667
- Testing
- Allogeneic Hematopoietic Stem Cell Transplantation, Clofarabine, Cyclosporine
- Where
- 4 sites in United States
- Volunteers
- 44 people
- Sponsor
- Fred Hutchinson Cancer Center
Leukemia, Myeloid, Acute
A Study of AC220 Given After Transplant in Subjects With Acute Myeloid Leukemia (AML)
The purpose of this study is to define a safe dose of AC220 when given as maintenance therapy after treatment with an allogeneic stem cell transplant.
- Trial name
- NCT01468467
- Testing
- AC220
- Where
- 5 sites in United States
- Volunteers
- 13 people
- Sponsor
- Daiichi Sankyo
Acute Myeloid Leukemia
Biology and Treatment Strategy of AML in Its Subgroups: Multicenter Randomized Trial by the German Acute Myeloid Leukemia Cooperative Group (AMLCG)
The study in patients with primary and secondary AML and high-risk MDS uses a risk-stratified, randomized design to evaluate the role of high-dose araC in induction, of G-CSF priming, and of autologous stem cell transplantation.
- Trial name
- NCT00266136
- Testing
- Cytarabine, Thioguanine, Daunorubicin
- Where
- Germany
- Volunteers
- 3,500 people
- Sponsor
- University Hospital Muenster
Frailty
AllogeneiC Human Mesenchymal Stem Cells (hMSC) in Patients With Aging FRAilTy Via IntravenoUS Delivery
The purpose of this study is to look at the safety of treatment with stem cells in patients with Frailty.
- Trial name
- CRATUS (NCT02065245)
- Testing
- Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs), Penicillin/Streptomycin-Free Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs)
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- Longeveron Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.